Focusing on treating patients with inflammatory bowel disease (IBD), this article featured discussions from the FutureIBD meeting. Chairing this meeting of international experts was Jean-Frederic Colombel, Icahn School of Medicine at Mount Sinai, New York, USA, and Remo Panaccione, University of Calgary, Canada.
Latest articlesAll articles
The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance
The over-production of TNF-α can lead to chronic inflammation and organ damage in immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis (RA), axial spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). Anti-TNF therapy is generally considered to be an effective, well-tolerated treatment option for the management of chronic inflammation in these conditions.
The Efficacy of Anti-TNFs in Immune-Mediated Disease
TNF-α is produced in high concentrations in chronic inflammatory disease, resulting in excessive inflammation which eventually leads to organ damage. The advent of anti-TNF therapy in clinical practice 20 years ago represented a significant change in the management of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA), axial spondylarthritis (SpA), psoriasis, and inflammatory bowel disease (IBD).